Drug Approval | December 20, 2021
WHO grants EUL for Covovax
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
The main objective of successive rounds of the NFHS is to provide reliable and comparable data relating to health and family welfare and other emerging issues
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
Bharat Biotech has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27th 2021
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
If approved it will bring a second source of MMR vaccine to the US market
Subscribe To Our Newsletter & Stay Updated
